Fritextsökning
Artiklar per år
Innehållstyper
-
Gustav Ceder: ”Hälsodata är Sveriges nya guld”
”Det här kommer att vara guld för Sverige.” Så sa socialminister Jakob Forssmed när jag stötte på honom på en solvarm bakgata i Visby, mellan kullerstenar och nästa seminarium. Almedalen i ett nötskal, skriver Gustav Ceder i en krönika.
-
Hann du läsa det här? Redaktionen tipsar
I solstolen, på tågresan eller i hängmattan kan det bli tid över för läsning. Här tipsar vi om några av de texter Life Science Sweden publicerat tidigare i år.
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudgements, outright quackery and “cures” that often caused more harm than good.
-
AlzeCure Signs Billion-Dollar Deal with Lilly
AlzeCure, a Huddinge-based biotech company, has signed a licensing agreement with Eli Lilly for one of its Alzheimer’s drug candidates.
-
Danish engineer wants to modernize the Nordic region’s biobanks
Biological samples are destroyed, lost and affected by temperature fluctuations more often than many people realize, according to German-Danish engineer Hans-Christoph Paul. Now he wants to see automated biobanks introduced in Sweden before the country falls behind.
-
Thermo Fisher’s lab in Gothenburg opens
Thermo Fisher’s clinical research business, PPD, is opening its first bioanalytical laboratory in Europe. The company chose Gothenburg for the new facility, which is now operational and expected to create 140 jobs.
-
Samuel Lagercrantz: ”Hansa och Bioarctic visar styrka – men klarar de nästa steg?”
, kan ta sig vidare och bli mer än one hit wonders.
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
GLP-1 profile leaves Novo Nordisk after 36 years
Lotte Bjerre Knudsen, one of the key figures behind Novo Nordisk’s success in obesity medicines, is leaving the company after more than three decades.
-
GSK eyes blockbuster potential – plans five new trials
GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced and hard-to-treat gynaecological cancers.
-
Sprint Bioscience bygger molekylerna som ska bli nya läkemedel
I Sprint Biosciences labb i Flemingsberg i Huddinge skapas molekyler som ingen annan tidigare byggt. Bolaget har specialiserat sig på preklinisk läkemedelsutveckling, och har i flera fall nått fram till affärer och partnerskap med större läkemedelsbolag.
-
Sprint Bioscience builds the molecules that will become new medicines
In Sprint Bioscience’s laboratory in Flemingsberg, Huddinge, molecules are being created that no one has ever built before. The company specializes in preclinical drug development and has, in several cases, succeeded in securing deals and partnerships
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
A food-based strategy to stop gut infections early
Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier by adding specially engineered binding proteins directly to food and animal feed.
-
Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”
The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well as our R&D here in Uppsala, we are building resilience for decades, not quarters,” says Santhosh Nair of Thermo Fisher.
-
National cord blood bank resumes collection
The collection of umbilical cord blood is now resuming during planned caesarean sections at Östra Hospital in Gothenburg. The blood remaining in the placenta and umbilical cord after birth contains stem cells that can be used to treat conditions including leukaemia and severe immunodeficiency disorders.
-
We are expanding our English-language coverage
Over a period of four weeks, one of Life Science Sweden's regular daily newsletters is being published entirely in English. The aim is to meet increasing demand and evaluate reader interest. (Swedish version below)
-
International medical graduates leave Sweden in high numbers
Three years after completing their studies, 46 percent of international doctoral students who graduated in the medical field had left the country. This is shown in Statistics Sweden’s (SCB) analysis of researchers who graduated between 2017 and 2020.
-
More than 150 jobs cut as Merck scales back vaccin production
Merck & Co, known as MSD in Europe, is hitting the brakes following a sharp decline in demand for its HPV vaccine Gardasil. Production at its facility in Durham, North Carolina, is now being halted, with more than 150 employees facing redundancy.
-
Samuel Lagercrantz: ”Obesity, blockbusters and Swedish biotech”
The development of technologies to bypass the blood-brain barrier is particularly exciting right now, as it holds the potential to unlock new treatments for a range of neurological diseases, according to Samuel Lagercrantz.
-
Anna Törner: ”Drug prices – an important driver of innovation”
We live under the illusion that no price is too high when it comes to health, but that simply isn’t true, writes Anna Törner.
-
End of bone‑sawing? New laser cuts to record depths
Saw, drill and chisel are a bone surgeon’s best friends today – but soon the laser may also find its place in that toolbox. Researchers in Switzerland have discovered a method for cutting significantly deeper and faster with a surgical laser than has previously been possible.
-
Lost in the recruitment process? How hiring really works today
As recruitment becomes increasingly automated, candidates are expected to adapt to both human and algorithmic decision-making. Career coach Tina Persson outlines why the process feels unfair – and how jobseekers can approach it more strategically.
-
Novo Nordisk strengthens board after turbulent year
Changes to Novo Nordisk’s board continue. Following last year’s sweeping restructuring, the Danish obesity drugmaker is now nominating two new directors with extensive experience in the pharmaceutical industry.
BREAKING